Explore
Validate
Learn
Western blot
Immunocytochemistry
ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [15]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-804-806-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Product name
- LAG-3 (human) monoclonal antibody (17B4)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- Purified.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 17B4
- Vial size
- 100 μg
- Storage
- -20°C
- Handling
- Avoid freeze/thaw cycles.
Submitted references Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling.
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway.
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.
Gulati N, Suárez-Fariñas M, Correa da Rosa J, Krueger JG
F1000Research 2015;4:149
F1000Research 2015;4:149
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Dec 15;18(24):6758-70
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Dec 15;18(24):6758-70
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K
Proceedings of the National Academy of Sciences of the United States of America 2010 Apr 27;107(17):7875-80
Proceedings of the National Academy of Sciences of the United States of America 2010 Apr 27;107(17):7875-80
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Casati C, Camisaschi C, Novellino L, Mazzocchi A, Triebel F, Rivoltini L, Parmiani G, Castelli C
Journal of immunology (Baltimore, Md. : 1950) 2008 Mar 15;180(6):3782-8
Journal of immunology (Baltimore, Md. : 1950) 2008 Mar 15;180(6):3782-8
Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling.
Oberle N, Eberhardt N, Falk CS, Krammer PH, Suri-Payer E
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 15;179(6):3578-87
Journal of immunology (Baltimore, Md. : 1950) 2007 Sep 15;179(6):3578-87
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK
Blood 2006 Feb 15;107(4):1332-41
Blood 2006 Feb 15;107(4):1332-41
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors.
Triebel F, Hacene K, Pichon MF
Cancer letters 2006 Apr 8;235(1):147-53
Cancer letters 2006 Apr 8;235(1):147-53
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Oct 1;11(19 Pt 1):6916-23
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Oct 1;11(19 Pt 1):6916-23
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.
Maçon-Lemaître L, Triebel F
Immunology 2005 Jun;115(2):170-8
Immunology 2005 Jun;115(2):170-8
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway.
Di Carlo E, Cappello P, Sorrentino C, D'Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F
The Journal of pathology 2005 Jan;205(1):82-91
The Journal of pathology 2005 Jan;205(1):82-91
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
Demeure CE, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F
European journal of cancer (Oxford, England : 1990) 2001 Sep;37(13):1709-18
European journal of cancer (Oxford, England : 1990) 2001 Sep;37(13):1709-18
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.
Hannier S, Tournier M, Bismuth G, Triebel F
Journal of immunology (Baltimore, Md. : 1950) 1998 Oct 15;161(8):4058-65
Journal of immunology (Baltimore, Md. : 1950) 1998 Oct 15;161(8):4058-65
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, Maigret B, Dréano M, Triebel F
Proceedings of the National Academy of Sciences of the United States of America 1997 May 27;94(11):5744-9
Proceedings of the National Academy of Sciences of the United States of America 1997 May 27;94(11):5744-9
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.
Huard B, Gaulard P, Faure F, Hercend T, Triebel F
Immunogenetics 1994;39(3):213-7
Immunogenetics 1994;39(3):213-7
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.
Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, Auffray C, Triebel F, Piatier-Tonneau D
The Journal of experimental medicine 1992 Aug 1;176(2):327-37
The Journal of experimental medicine 1992 Aug 1;176(2):327-37
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Western blot analysis of LAG-3 mAb (17B4) (Prod. No. ALX-804-806): Lane 1: MW marker, Lane 2: LAG-3 (human):Fc (human), (recombinant) (Prod. No. ALX-522-078).
